ClinConnect ClinConnect Logo
Search / Trial NCT03231891

Inherited CAncer REgistry

Launched by VANDERBILT-INGRAM CANCER CENTER · Jul 24, 2017

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

ClinConnect Summary

The Inherited CAncer REgistry (ICARE) is a research initiative designed for individuals interested in understanding more about inherited cancer risks. This registry allows participants to contribute to important studies that focus on how genetics can influence cancer. By joining, you’ll not only help advance cancer research but also receive valuable information about your own health and genetic risks. Each participant will fill out a consent form and answer some questions about their health, and then check in every two years.

If you’re at least 18 years old and willing to give your consent, you may be eligible to participate in this study. There’s no cost to join, and you can sign up either online or by mail. As a participant, you’ll receive educational newsletters twice a year with updates on cancer genetics, and you’ll have access to expert-led discussions on various related topics. If you’re interested in learning more or want to join the study, please visit the ICARE website for further information.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • At least 18 years of age
  • Able and willing to provide informed consent

About Vanderbilt Ingram Cancer Center

The Vanderbilt-Ingram Cancer Center (VICC) is a leading academic institution dedicated to advancing cancer research, prevention, and treatment. As a National Cancer Institute-designated Comprehensive Cancer Center, VICC integrates cutting-edge scientific discovery with clinical excellence to develop innovative therapies and improve patient outcomes. The center is committed to fostering a collaborative environment that brings together experts from diverse fields to address the complexities of cancer. Through rigorous clinical trials, VICC aims to translate groundbreaking research into effective treatment options, ensuring patients have access to the latest advancements in cancer care.

Locations

Nashville, Tennessee, United States

Patients applied

0 patients applied

Trial Officials

Tuya Pal, MD

Principal Investigator

Vanderbilt University Medical Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials